MapLight Therapeutics, Inc.
MPLT$1.31B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaREDWOOD CITY114 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
6
Next Catalyst
Jun 25, 2026
5dMarket Overview
Stock performance and key metrics
MPLT News
Catalyst Timeline
6 upcoming, 0 past
EarningsNext
MPLT Earnings Report
Jun 25, 2026Confirmed
EPS Est: $-0.91 | FQ end 2026-03
5 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
ML-007C-MA
Psychosis Associated With Alzheimer's Disease
ML-004 (IR)/(ER) tablet
Autism Spectrum Disorder
ML-007C-MA BID
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease | - | - |
ML-004 (IR)/(ER) tablet | Phase 2 | Autism Spectrum Disorder | - | - |
ML-007C-MA BID | Phase 2 | Schizophrenia | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply